Karmanos Cancer Institute first to receive new FDA-approved treatment for advanced liver cancer

Innovative treatment uses radio frequency to target and reduce cancerous tumors

DETROIT, Nov. 13, 2023 /PRNewswire/ -- Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that it will be the first provider in the country to offer patients the new FDA-approved TheraBionic P1 device for the treatment of advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. HCC accounts for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months. The innovative TheraBionic P1 device is a novel at-home treatment that emits low levels of radio-frequency electromagnetic fields that block the growth of tumor cells without affecting healthy tissue. The device is approved for treating patients 18 years of age or older who fail first- and second-line therapies.

“Twenty years ago, I hypothesized that radio frequencies might block tumor growth and hoped one day it could make a meaningful difference and become the future of cancer treatment, so it’s incredibly rewarding to see the TheraBionic P1 device finally come to market starting with Karmanos, an organization on the cutting edge of cancer innovation, research and novel therapies,” said Boris Pasche, M.D., Ph.D., FACP, president and CEO of the Barbara Ann Karmanos Cancer Institute, CEO of TheraBionic, Inc. and co-inventor of the TheraBionic P1 device. “Advanced hepatocellular carcinoma is an incurable cancer, so the FDA’s approval of this non-invasive treatment option is transformative as physicians across the country will now have access to this revolutionary treatment that has proven to prolong the life of those battling the disease.”

TheraBionic P1 is a hand-held device that produces low levels of 27.12 MHz radiofrequency electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies. The device, which is fully portable for in-home use, is coupled with a spoon-shaped antenna placed on the patient’s tongue during treatment administered in three, one-hour sessions per day, delivering low levels of radiofrequency electromagnetic fields throughout the patient’s body. The radiofrequency levels delivered during treatment are lower than those generated by cellular phones when held close to the body.

Watch Dr. Pasche describe the benefits of the TheraBionic P1 device and how to use it here.

“Often, patients with advanced hepatocellular carcinoma who fail first- and second-line therapies have severely impaired liver function, so additional treatment options are limited or nonexistent. We are very pleased that the TheraBionic P1 device will provide our patients with an effective alternative treatment option,” said Anthony Shields, M.D., Ph.D., medical oncologist and leader of the Gastrointestinal and Neuroendocrine Multidisciplinary Team at Karmanos. “We’re excited to be the first cancer hospital in the United States to offer this innovative therapy that is safe, well tolerated, and has the clinical benefit of reducing tumor growth.”

“The TheraBionic P1 device has a proven response rate that is comparable to the best treatment options available for advanced hepatocellular carcinoma, so it is immensely gratifying to provide patients access to this easy-to-use, at-home solution that can critically impact their quality of life,” said Dr. Pasche.

No serious adverse events have been reported with the use of the TheraBionic P1 device, even after more than six years of continuous use. Physicians treating patients who meet the criteria of TheraBionic P1 device can prescribe treatment, and TheraBionic will ship the device to the practice.

Multiple clinical trials are underway studying the TheraBionic P1 device’s impact on various other cancers such as breast, brain, ovarian, gallbladder, pancreatic and prostate.

About the Barbara Ann Karmanos Cancer Institute
Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown Detroit. With 16 network sites, Karmanos delivers world-renowned care and access to clinical trials throughout Michigan and northern Ohio. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit www.karmanos.org. Follow Karmanos on Facebook, Twitter, LinkedIn and YouTube.

About TheraBionic, Inc.
TheraBionic, Inc. is an innovative medical device company focused on transforming the lives of patients with difficult to treat cancers. TheraBionic, Inc. patented low-level, tumor-specific radio frequencies administered via the TheraBionic P1 device is FDA approved in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The results of more than two decades of studies have indicated that the tumor-specific radio frequencies are effective in tumor shrinkage, blocking new cancer cell growth, and overall increased survival rates. Boris Pasche, M.D., Ph.D., and Alexandre Barbault are co-inventors of TheraBionic technology and co–founders of TheraBionic, Inc. TheraBionic, Inc. is based in Bloomfield Hills, MI. TheraBionic P1 is slated for commercial availability in the United States by 1st quarter of 2024.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karmanos-cancer-institute-first-to-receive-new-fda-approved-treatment-for-advanced-liver-cancer-301985513.html

SOURCE Karmanos Cancer Institute